null

null

null

null

null

null

null

null

null

null

null

null

null

null

0.69x Total Debt / Equity (Moderate leverage)

Moderate-high; Pulmonx carries ~$100M+ debt with variable exposure; 200bps rate rise adds ~$2M annual interest, pressuring cash burn for pre-profitability medtech firm

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Taiwan/China semiconductor components for Chartis system electronics; single-source European catheter manufacturing in Germany creating EU regulatory and logistics chokepoint

EUR (~40% international revenue), GBP, and CHF exposure; EUR devaluation 10% vs USD reduces reported revenue ~4%; hedging minimal given company size

Primary markets: USA, Germany, UK; EUR and GBP devaluation risk meaningful; ~30-35% revenue outside US with limited natural hedging or formal FX derivative program

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Yes; single-source supplier for Zephyr Endobronchial Valve components; no qualified alternate manufacturer disclosed, creating non-substitutable critical dependency above 30% threshold

Medical device hardware company; cloud dependency limited to data analytics and CRM; 30-day termination disruptive but not existential; 60-90 day recovery via alternative hosting feasible

Procedure-driven consumables model; cloud termination affects sales force tools and Chartis data upload but does not halt core bronchoscopic valve procedure revenue

Low API coupling risk; Pulmonx is a hardware/procedure company with minimal third-party API dependencies in core revenue-generating product stack

Very low; revenue derived from physical medical device sales and procedures; no investment contract, profit-sharing, or token structure; Howey Test inapplicable

Very High

Moderate GDPR exposure; patient procedure data collected in EU requires compliant data processing agreements; CCPA applies to US patient data; no major violations disclosed but ongoing compliance cost

Low; Pulmonx holds ~60-70% of bronchoscopic lung volume reduction market but market is niche and nascent; no current DOJ/FTC scrutiny identified; competition from Olympus/BTG growing

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~85% transactional (single-use Zephyr valves per procedure); ~15% capital equipment (Chartis system); minimal recurring contract revenue; highly procedure-volume dependent

Per-procedure consumable valve sales (~$3,000-5,000 per case); razor-and-blade model with Chartis assessment system as installed base driver for valve pull-through

Premium single-use device pricing; reimbursement-anchored; CMS APC reimbursement rate caps effective price ceiling; hospital budget pressure limits list price increases above 3-5% annually

Moderate; first-mover in BLVR with strong clinical evidence but reimbursement dependency constrains unilateral price increases; rated 6/10 pricing power

74.2% Gross Margin (Premium (>60%))

No free-rider leakage; physical consumable requires purchase; however physician/hospital adoption churn is real if procedural volumes disappoint or competitor gains reimbursement parity

Headcount-linear in commercial scaling; doubling revenue requires proportional field sales/clinical specialist additions; gross margin ~70%+ but SG&A scales with territory expansion

Sublinear at maturity but currently linear; each new hospital account requires dedicated clinical support rep; marginal cost of incremental procedure ~$1,500 in commercial support cost

Not applicable; Pulmonx operates direct sales model, not franchise; no franchise network compliance risk

At 10x scale, CAC likely improves 30-40% via brand recognition and KOL network effects; however clinical training cost per hospital remains fixed at ~$15,000-25,000 per account

Weak direct network effects; clinical evidence and physician training community create modest indirect network effect; durability moderate as competitor data could erode differentiation within 5-7 years

-41.3% Return on Assets (Negative equity)

Moderate recession resistance; COPD procedure is elective-deferrable but addresses severe unmet need; hospital capex cuts more likely to affect Chartis capital sales than valve consumables

Interventional pulmonologists and thoracic surgeons at academic medical centers and large community hospitals; top 10 accounts likely represent 25-35% of US revenue

Hospital value analysis committees and health system GPOs controlling device approvals; payer concentration risk via CMS reimbursement policy representing majority of BLVR patient funding

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.5% CapEx / Revenue (Low-CapEx Asset-Light)

0001127537

LUNG